Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial

Elena Tsourdi; Aliya Khan; Mishaela R. Rubin; Dolores Shoback; Schwarz Peter; Lynn Kohlmeier; Andrea Palermo; B.L. Clarke; Erik Fink Eriksen; Filomena Cetani; Rajesh Kumar Jain; Carol Zhao; Bryant Lai; Jenny Ukena; Christopher T. Sibley; Michael S. Ominsky; Aimee Shu; Lars Rejnmark

doi:10.1055/s-0044-1782054

Abstract

Introduction: Evaluate the temporal changes in and relationship between skeletal endpoints in response to palopegteriparatide (TransCon PTH), a prodrug with sustained release of PTH(1-34), in individuals with chronic hypoparathyroidism.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tsourdi et al. (2024) studied this question.

synapsesocial.com/papers/68e74453b6db6435876bd422 https://doi.org/10.1055/s-0044-1782054

View at Publisher

Ask AI

Bookmark

Share

Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial

Abstract

Discussion

Cite This Study

Improved Skeletal Dynamics in Adults Treated With Palopegteriparatide for Hypoparathyroidism: 52-Week Analysis of Phase 3 PaTHway Trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading